The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

December 1, 2014 • By Peter H. Schur, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Know your labs
Laboratory testing is essential in the diagnosis and management of patients with rheumatic disease.

Editor’s note: This article originally appeared in The Rheumatologist in a two-part series in February and April 2009. The topic and this article remain highly relevant, and Dr. Schur has updated it here.

You Might Also Like
  • The Value of Repeat Antibody Testing in Lupus Patients
  • Letters: Detecting Lyme Disease May Require Thorough Testing
  • Whole-Body MRI, Ultrasound Imaging May Aid in Early Rheumatic Disease Diagnosis, Treatment
Explore This Issue
December 2014
Also By This Author
  • Know Your Labs

Laboratory testing is an essential element in the diagnosis and management of patients with rheumatic disease. This article focuses on a diverse array of serological markers that can provide unique information on the status of the patient’s immune system that is important in clinical evaluation as well as scientific inquiry. These tests help in the diagnosis of a particular disease, and importantly, they may help monitor disease activity. Indeed, immunological testing represents one of the bedrocks of rheumatology and is a distinguishing feature of our specialty.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although there are many available tests, the approach to serology follows the traditional approach of any laboratory study. Critical in the interpretation of any serological test is determining its sensitivity (i.e., that proportion of patients with the target disorder who have a positive test), specificity (i.e., that proportion of patients who are free of the target disorder and have negative or normal test results), and positive and negative predictive values, which calculate the likelihood that disease is present or absent based on test results using the test’s sensitivity, specificity and the probability of disease before the test is performed (pretest probability). This review covers data on antinuclear antibodies (ANAs) and tests for rheumatoid arthritis (RA).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Table 1: Sensitivity of the ANA in Autoimmune & Nonrheumatic Disease
click for large version
Table 1: Sensitivity of the ANA in Autoimmune & Nonrheumatic Disease

Antinuclear Antibodies

ANAs are the signature autoantibodies of the rheumatic disease and are tested in many clinical scenarios.1-3 These antibodies are usually detected by immunofluorescent (IF) techniques, utilizing Hep-2 cell lines, and specific antinuclear antibodies are detected by solid-phase immuno­assays—for example, an ELISA. One hundred and eighty autoantibodies have been described so far in patients with systemic lupus erythematosus (SLE).58 The IF ANA is generally screened at a dilution (i.e., titer) of 1:40, and, if positive, serial dilutions are carried out until a dilution is negative. Most labs titer to 1:1280, but some go higher. It is not clear whether titering higher is clinically useful, because the titer of an ANA usually does not correlate with clinical activity.

The IF ANA test is especially useful as an initial screen for patients suspected of having systemic lupus erythematosus (SLE). ANA testing is also useful for the evaluation of patients with other suspected rheumatic conditions including Sjögren’s syndrome, mixed connective tissue disease (MCTD), drug-induced lupus erythematosus, dermato-/polymyositis, scleroderma, adult and juvenile arthritis and autoimmune hepatitis. However, the presence of an ANA does not signify the presence of illness, because these antibodies may also be found in otherwise normal individuals. As shown in Table 1 (left), the sensitivity of the ANA for a particular autoimmune disease can vary widely.

Pages: 1 2 3 4 5 6 7 8 9 10 11 | Single Page

Filed Under: Practice Management, Quality Assurance/Improvement Tagged With: ANA titer, antinuclear antibodies, antinuclear antibody test, Diagnosis, lab test, labs, patient care, Rheumatic Disease, Rheumatoid arthritis, rheumatologist, Schur, Scleroderma, Sjögren's syndromeIssue: December 2014

You Might Also Like:
  • The Value of Repeat Antibody Testing in Lupus Patients
  • Letters: Detecting Lyme Disease May Require Thorough Testing
  • Whole-Body MRI, Ultrasound Imaging May Aid in Early Rheumatic Disease Diagnosis, Treatment
  • State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)